Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Two isomeric series of dual binding site acetylcholinesterase (AChE) inhibitors have been designed, synthesized, and tested for their ability to inhibit AChE, butyrylcholinesterase, AChE-induced and self-induced beta-amyloid (Abeta) aggregation, and beta-secretase (BACE-1) and to cross blood-brain barrier. The new hybrids consist of a unit of 6-chlorotacrine and a multicomponent reaction-derived pyrano[3,2-c]quinoline scaffold as the active-site and peripheral-site interacting moieties, respectively, connected through an oligomethylene linker containing an amido group at variable position. Indeed, molecular modeling and kinetic studies have confirmed the dual site binding of these compounds. The new hybrids, and particularly 27, retain the potent and selective human AChE inhibitory activity of the parent 6-chlorotacrine while exhibiting a significant in vitro inhibitory activity toward the AChE-induced and self-induced Abeta aggregation and toward BACE-1, as well as ability to enter the central nervous system, which makes them promising anti-Alzheimer lead compounds.
Camps
Pelayo
P
Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.
Formosa
Xavier
X
Galdeano
Carles
C
Muñoz-Torrero
Diego
D
Ramírez
Lorena
L
Gómez
Elena
E
Isambert
Nicolás
N
Lavilla
Rodolfo
R
Badia
Albert
A
Clos
M Victòria
MV
Bartolini
Manuela
M
Mancini
Francesca
F
Andrisano
Vincenza
V
Arce
Mariana P
MP
Rodríguez-Franco
M Isabel
MI
Huertas
Oscar
O
Dafni
Thomai
T
Luque
F Javier
FJ
D000110:Acetylcholinesterase / Q000378:metabolism*; D000544:Alzheimer Disease / Q000188:drug therapy*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D002091:Butyrylcholinesterase / Q000378:metabolism; D002417:Cattle; D002800:Cholinesterase Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D007536:Isomerism; D008567:Membranes, Artificial; D051379:Mice; D008958:Models, Molecular; D008968:Molecular Conformation; D010539:Permeability; D011485:Protein Binding / Q000187:drug effects; D013619:Tacrine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
C098212:6-chlorotacrine; D016229:Amyloid beta-Peptides; D002800:Cholinesterase Inhibitors; D008567:Membranes, Artificial; D013619:Tacrine; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D053829:Amyloid Precursor Protein Secretases